Firms Commit To Local Production As Turkey Seeks Import Cuts
Executive Summary
The Turkish government’s drive to increase the local production of medicines has begun to yield results, with companies so far committing to shift over $500m in sales to domestic manufacture, as the country plans to cut around $685m from its drug imports bill in the first year of the program.
You may also be interested in...
New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus
Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.
New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus
Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.